Tiny trial probes immune cells against rare testicular cancer
NCT ID NCT05634785
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This phase 2 study tested a new treatment using a patient's own immune cells (T cells) engineered to target CD30, a protein on certain germ cell tumors. Only 2 adults with nonseminomatous germ cell tumors who had prior treatment were enrolled. The main goal was to collect blood and tumor samples to see if the modified cells stay in the body and to learn how to improve future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
Chapel Hill, North Carolina, 27599, United States
Conditions
Explore the condition pages connected to this study.